Abstract
The last three years have been spent combating COVID-19, and governments have been seeking optimal solutions to minimize the negative impacts on societies. Although two types of testing have been performed for this—follow-up testing for those who had close contact with infected individuals and mass-testing of those with symptoms—the allocation of resources has been controversial. Mathematical models such as the susceptible, infectious, exposed, recovered, and dead (SEIRD) model have been developed to predict the spread of infection. However, these models do not consider the effects of testing characteristics and resource limitations. To determine the optimal testing strategy, we developed a testing-SEIRD model that depends on testing characteristics and limited resources. In this model, people who test positive are admitted to the hospital based on capacity and medical resources. Using this model, we examined the infection spread depending on the ratio of follow-up and mass-testing. The simulations demonstrated that the infection dynamics exhibit an all-or-none response as infection expands or extinguishes. Optimal and worst follow-up and mass-testing combinations were determined depending on the total resources and cost ratio of the two types of testing. Furthermore, we demonstrated that the cumulative deaths varied significantly by hundreds to thousands of times depending on the testing strategy, which is encouraging for policymakers. Therefore, our model might provide guidelines for testing strategies in the cases of recently emerging infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Cooperative Study Program of Exploratory Research Centre on Life and Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Transformative Research Areas (B) [grant number 21H05170], and a Grant-in-Aid for Scientific Research (B) (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exempted from ethical review because no human or animal subjects or specimens are involved.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Language edited thoroughly. Rebuilt abstract and introduction. Update figures. Added statistic presentation.
Data Availability
All relevant data are within the study and its supporting information files.